HTC
AZN icon

Haverford Trust Company’s AstraZeneca AZN Stock Holding History

Haverford Trust Company’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$384K Sell
2,026
-1,888
-48% -$355K ﹤0.01% 337
2026
Q1 		$758K Hold
3,914
– – 0.01% 254
2025
Q4 		$720K Buy
3,914
+428
+12% +$75.1K 0.01% 256
2025
Q3 		$535K Sell
3,486
-800
-19% -$121K ﹤0.01% 279
2025
Q2 		$599K Buy
4,286
+1,329
+45% +$186K 0.01% 271
2025
Q1 		$435K Buy
2,957
+16
+0.5% +$2.31K ﹤0.01% 304
2024
Q4 		$385K Sell
2,941
-83
-3% -$11.6K ﹤0.01% 321
2024
Q3 		$471K Sell
3,024
-15
-0.5% -$2.42K ﹤0.01% 312
2024
Q2 		$474K Buy
3,039
+15
+0.5% +$2.26K 0.01% 301
2024
Q1 		$410K Buy
3,024
+800
+36% +$106K ﹤0.01% 307
2023
Q4 		$300K Sell
2,224
-706
-24% -$91.8K ﹤0.01% 327
2023
Q3 		$397K Sell
2,930
-159
-5% -$21.7K ﹤0.01% 283
2023
Q2 		$442K Buy
3,089
+303
+11% +$44.6K 0.01% 281
2023
Q1 		$387K Buy
2,786
+840
+43% +$113K ﹤0.01% 288
2022
Q4 		$264K Sell
1,946
-886
-31% -$111K ﹤0.01% 305
2022
Q3 		$311K Sell
2,832
-351
-11% -$44.5K ﹤0.01% 290
2022
Q2 		$421K Sell
3,183
-111
-3% -$14.6K 0.01% 254
2022
Q1 		$437K Buy
3,294
+886
+37% +$106K 0.01% 267
2021
Q4 		$281K Buy
2,408
+201
+9% +$23.7K ﹤0.01% 317
2021
Q3 		$265K Buy
2,207
+212
+11% +$24.7K ﹤0.01% 313
2021
Q2 		$239K Sell
1,995
-500
-20% -$54.9K ﹤0.01% 322
2021
Q1 		$248K Hold
2,495
– – ﹤0.01% 284
2020
Q4 		$249K Buy
+2,495
New +$264K ﹤0.01% 266
2014
Q1 		– Sell
-3,471
Closed -$206K – 212
2013
Q4 		$206K Buy
+3,471
New +$189K 0.01% 252

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Haverford Trust Company's AZN Position: Q2 2026 in Review

Haverford Trust Company reduced its AstraZeneca (AZN) stake by 48% in Q2 2026, selling an estimated $355K and leaving 2,026 shares worth $384K. The position accounts for ﹤0.01% of the portfolio, ranked #337.

Haverford Trust Company first reported a position in AZN in Q4 2013 and has held it in 24 quarters since. The position peaked at $758K in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Haverford Trust Company held 2,026 shares of AstraZeneca worth $384K as of Q2 2026.
  • Haverford Trust Company sold 1,888 AstraZeneca shares in Q2 2026, an estimated $355K.
  • AstraZeneca made up ﹤0.01% of Haverford Trust Company's portfolio in Q2 2026, its #337 holding.
  • Haverford Trust Company first reported a position in AstraZeneca in Q4 2013 and has held it in 24 quarters since.
  • Haverford Trust Company's AstraZeneca position peaked at $758K in Q1 2026.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Haverford Trust Company's 13F filing for Q2 2026, filed 12 Aug 2026.